Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 01/20 11:31:23 am
86.01 CHF   +0.57%
10:59aNOVARTIS AG : Credit Suisse reiterates its Neutral rating
MD
07:51aNOVARTIS AG : Jefferies keeps its Buy rating
MD
01/19NOVARTIS AG : JP Morgan reaffirms its Sell rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVARTIS AG : Barclays reaffirms its Sell rating

11/27/2020 | 07:09am EST

In a research note published by Emily Field, Barclays advises its customers to Sell the stock. The target price is still set at CHF 75.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
BARCLAYS PLC -0.37% 146.32 Delayed Quote.0.12%
NOVARTIS AG 0.57% 86.01 Delayed Quote.2.24%
All news about NOVARTIS AG
10:59aNOVARTIS AG : Credit Suisse reiterates its Neutral rating
MD
07:51aNOVARTIS AG : Jefferies keeps its Buy rating
MD
01/19NOVARTIS AG : JP Morgan reaffirms its Sell rating
MD
01/19Novartis, GSK Kick Off Exploration of African Genetic Diversity to Improve Tr..
MT
01/19Novartis, GlaxoSmithKline Launch Research on Genetic Diversity in Africa
MT
01/19GSK, Novartis Announce Collaboration To Support Scientific Research Into Gene..
RE
01/19NOVARTIS : GSK and Novartis announce collaboration to support scientific researc..
AQ
01/19NOVARTIS : and GSK announce collaboration to support scientific research into ge..
PU
01/18NOVARTIS : to Continue Global Gene Therapy Access Program in 2021
MT
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
More news
Financials (USD)
Sales 2020 49 196 M - -
Net income 2020 8 204 M - -
Net Debt 2020 19 213 M - -
P/E ratio 2020 23,5x
Yield 2020 3,67%
Capitalization 196 B 220 B -
EV / Sales 2020 4,37x
EV / Sales 2021 3,99x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 108,90 $
Last Close Price 86,01 $
Spread / Highest target 63,7%
Spread / Average Target 26,6%
Spread / Lowest Target -4,48%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.24%218 823
JOHNSON & JOHNSON3.43%428 525
ROCHE HOLDING AG2.98%307 190
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160
ABBVIE INC.4.69%198 051